Pancreatic cancer has a grim prognosis. It is usually detected after the disease has spread, and chemotherapy tends to do little to slow the cancer’s growth. Even with treatment, most patients live only about six months after they are diagnosed with the disease.
Researchers in Professor David Tuveson’s laboratory at Cold Spring Harbor Laboratory (CSHL) think it’s possible to do better with a different type of treatment. Part of the problem, they say, is that cancer cells in the pancreas are protected by the dense matrix that surrounds them. The matrix is a mixture of extracellular components and noncancerous cells known as the stroma. All solid tumors contain stroma. In pancreatic cancers, this fibrous material is particularly abundant, making up nearly 90 percent of a tumor’s mass. This stroma impedes anticancer drugs’ from getting to their targets. Additionally, stromal cells secrete factors that actually help the tumors grow.
Overcoming the stroma’s protective influence has been challenging, but new leads from Tuveson’s team, as reported on October 26, 2018 in the journal Cancer Discovery, point to a promising strategy. In fact, the new findings suggest that drugs which target the right cellular pathways can do more than just thwart tumor-supporting cells in the stroma. They may recruit them into the anticancer fight.
A key element of the stroma is a type of cell called a fibroblast. Fibroblasts manufacture the stroma’s connective tissue. They also generate factors that promote cancer cell growth and prevent the immune system from attacking the cancerous cells. Last year Tuveson’s team discovered that the stroma of pancreatic tumors contains at least two types of fibroblasts. One type show features known to support tumor growth, the other type appear to have the opposite effect.
The good news is that the fibroblasts’ identities are not fixed. With the right cues, tumor-promoting fibroblasts can become tumor-restrictors.
“These cells can convert into one another, depending on the cues they get from the microenvironment and from the cancer cells,” explains Giulia Biffi, a postdoctoral researcher in Tuveson’s lab who led the new study. “This is potentially useful because, in theory, you can shift the tumor-promoting cells to tumor-restraining, rather than just depleting the tumor-promoting cells.”
In this new report, Biffi and her colleagues have identified specific molecular signals released by cancer cells that determine fibroblasts’ character within pancreatic tumors. They have discovered that one such molecule, IL-1, drives fibroblasts to take on a tumor-promoting identity. They have also shown how another molecule, TGF-beta, overrides that signal and keeps fibroblasts in a potentially anticancer state even when IL-1 is present.
The researchers are now exploring what happens to pancreatic tumors when they manipulate IL-1 and TGF-beta signaling and convert tumor-promoting fibroblasts to a more beneficial state. They will also investigate what happens when they target these pathways in combination with chemotherapy or cancer immunotherapies. Ultimately, Biffi says, patients may benefit most from a combination of therapies that target both the cancer cells and parts of the microenvironment that support their growth.
Learn more: Turning cells against pancreatic cancer
The Latest on: Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pancreatic cancer
- First pancreatic cancer patient dosed in Radiopharm studyon February 28, 2024 at 11:03 pm
Radiopharm Theranostics says it has dosed its first pancreatic cancer patient in the initial phase of a study aimed at providing doctors with an enhanced screening process for the lethal and ...
- SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Pancreatic Canceron February 28, 2024 at 3:59 pm
SEOUL, South Korea, Feb. 29, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on Feb 27 that the US FDA had granted an orphan drug designation for pancreatic cancer for ...
- Scientists discover mucus allows young pancreatic cancer cells to grow but may also prevent a deadly transformationon February 28, 2024 at 1:48 pm
Knowing exactly what's inside a tumor can maximize our ability to fight cancer. But that knowledge doesn't come easy. Tumors are clusters of constantly changing cancer cells. Some become common cancer ...
- What you need to know about pancreatic canceron February 28, 2024 at 12:03 pm
Pancreatic cancer is called a “silent killer” because it is usually not found until it has spread from the pancreas, making it extremely difficult to treat. Pancreatic cancer, like other cancers, ...
- Researchers looking for patients to participate in pancreatic cancer vaccine trialon February 28, 2024 at 11:02 am
This trial is testing a vaccine to treat pancreatic cancer. Researchers said it could have a huge impact in pancreatic cancer which is often not discovered until later stages. The study is designed ...
- What is pancreatic cancer? All you need to know about its warning signson February 28, 2024 at 3:19 am
Pancreatic cancer is a serious illness that affects the pancreas, an essential organ in the body's digestive system. Despite being relatively rare, it's one of the deadliest forms of cancer, largely ...
- Pankaj Udhas suffered from pancreatic cancer, all about the diseaseon February 27, 2024 at 12:34 am
Legendary ghazal singer Pankaj Udhas passed away on Monday reportedly due to pancreatic cancer. Symptoms to treatment, all you want to know about the cancer.
- Ask the doctors: Researchers use AI to detect pancreatic cancer sooneron February 26, 2024 at 4:00 pm
Dear Doctors: A dear friend was diagnosed with pancreatic cancer. It was so advanced, he died just a month later. I recently saw a discussion on television about using AI to detect it early, while it ...
- Increase in women being diagnosed with pancreatic canceron February 26, 2024 at 7:53 am
New statistics reveal an increase in cases of pancreatic cancer being diagnosed in women. The figures, released by Cancer Research UK (CRUK), came from comparing incidences of pancreatic cancer in the ...
via Bing News